Not_yet_recruitingNANCT06763952

Multicenter National Parallel Cluster Randomized Controlled Superiority Trial Comparing an Artificial Intelligence-Based Screening Strategy to Usual Care for Improving Eye-Care Follow-Up Among Patients With Diabetes (AI-BRIDGE Trial)

Sponsor: University of Wisconsin, Madison

Trial Details

Condition	Diabetic Retinopathy, Diabetes Mellitus
Intervention	AI
Phase	NA
Status	Not_yet_recruiting
Participants	4,000
Est. Completion	1 May 2030
Last Updated	29 Apr 2026

Primary Outcome

Proportion of Participants Who Follow Up With Recommended Eye Care

Eligibility Criteria

Inclusion Criteria

Inclusion Criteria: * Diagnosed with type 1 or 2 diabetes * No known diabetic eye disease * Medicaid as their primary insurance * Not had an eye exam in the prior year Exclusion Criteria:

Trial Sites

Countries

United States

View Registry Entry

Related Analysis

Phase IV AI-BRIDGE Trial: Point-of-Care Diabetic Retinopathy Screening vs Standard Care — Addressing Health Equity in Primary Care

The AI-BRIDGE trial evaluates point-of-care diabetic retinopathy screening in primary care settings, targeting 4,000 Medicaid patients to address screening disparities. Results expected 2030.

Read full article →

This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service